Acute spinal cord injury, part I: pathophysiologic mechanisms.

Abstract:

:Spinal cord injury (SCI) is a devastating and common neurologic disorder that has profound influences on modern society from physical, psychosocial, and socioeconomic perspectives. Accordingly, the present decade has been labeled the Decade of the Spine to emphasize the importance of SCI and other spinal disorders. Spinal cord injury may be divided into both primary and secondary mechanisms of injury. The primary injury, in large part, determines a given patient's neurologic grade on admission and thereby is the strongest prognostic indicator. However, secondary mechanisms of injury can exacerbate damage and limit restorative processes, and hence, contribute to overall morbidity and mortality. A burgeoning body of evidence has facilitated our understanding of these secondary mechanisms of injury that are amenable to pharmacological interventions, unlike the primary injury itself. Secondary mechanisms of injury encompass an array of perturbances and include neurogenic shock, vascular insults such as hemorrhage and ischemia-reperfusion, excitotoxicity, calcium-mediated secondary injury and fluid-electrolyte disturbances, immunologic injury, apoptosis, disturbances in mitochondrion function, and other miscellaneous processes. Comprehension of secondary mechanisms of injury serves as a basis for the development and application of targeted pharmacological strategies to confer neuroprotection and restoration while mitigating ongoing neural injury. The first article in this series will comprehensively review the pathophysiology of SCI while emphasizing those mechanisms for which pharmacologic therapy has been developed, and the second article reviews the pharmacologic interventions for SCI.

journal_name

Clin Neuropharmacol

authors

Dumont RJ,Okonkwo DO,Verma S,Hurlbert RJ,Boulos PT,Ellegala DB,Dumont AS

doi

10.1097/00002826-200109000-00002

keywords:

subject

Has Abstract

pub_date

2001-09-01 00:00:00

pages

254-64

issue

5

eissn

0362-5664

issn

1537-162X

journal_volume

24

pub_type

杂志文章,评审
  • Seizure control after chronic pharmacotherapy in epileptic disorders beginning after 40 years of age.

    abstract::Few studies have been published on the pharmacologic response to treatment of patients whose seizures begin after 40 years of age. The purpose of this study was to assess the impact of chronic pharmacotherapy on the seizure control of such patients. We retrospectively studied the seizure frequency recorded during a 12...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199502000-00002

    authors: Hasegawa H,Kanner AM

    更新日期:1995-02-01 00:00:00

  • Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations.

    abstract::The authors compared the two portions of the OFF period in patients with Parkinson disease and response fluctuations: time to ON (the latency from levodopa intake to turning ON) and wearing off (time from termination of the beneficial dose effect until the time when the next dose was taken). Time to ON was more than t...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200307000-00009

    authors: Merims D,Djaldetti R,Melamed E

    更新日期:2003-07-01 00:00:00

  • Gabapentin treatment for muscle cramps: an open-label trial.

    abstract::To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200001000-00008

    authors: Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

    更新日期:2000-01-01 00:00:00

  • Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.

    abstract::A 34-year-old man presented with severe refractory depression. He had failed to respond to various antidepressants, augmentation therapy with lithium carbonate, and modified electroconvulsive therapy. Switching from amoxapine 150 mg/day to selegiline 7.5 mg/day, a selective monoamine oxidase type-B inhibitor, produced...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000171248.89726.2f

    authors: Higuchi H,Kamata M,Sugawara Y,Yoshida K

    更新日期:2005-07-01 00:00:00

  • The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis.

    abstract::The standard therapy for myasthenia gravis (MG) includes steroids and immunosuppressants, which have delayed onset of action and significant side effects. Plasmapheresis and intravenous immunoglobulin have been used mostly for the treatment of severe exacerbations. In the present study we examined the use of intraveno...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200105000-00010

    authors: Hilkevich O,Drory VE,Chapman J,Korczyn AD

    更新日期:2001-05-01 00:00:00

  • Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.

    abstract::A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31811510ed

    authors: Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

    更新日期:2008-05-01 00:00:00

  • Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.

    abstract::Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00002826-199417001-00002

    authors: Gagiano CA,Hart GA,Bodemer W,Schall R

    更新日期:1994-01-01 00:00:00

  • Fulminant CNS perivascular lymphocytic proliferation: association with sargramostim, a hematopoietic growth factor.

    abstract::Sargramostim (GM-CSF) therapy was instituted in a 49-year-old woman with hepatitis C on chronic interferon alpha-2b therapy. Within two weeks, she developed progressive confusion, lethargy, and gait disturbance. At autopsy 4 months later, diffuse perivascular nonmonoclonal lymphoid infiltrates were demonstrated throug...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Riggs JE,Mansmann PT,Cook LL,Schochet SS Jr,Hogg JP

    更新日期:1999-09-01 00:00:00

  • A multicenter Italian study of amineptine (Survector 100).

    abstract::This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00002826-198912002-00006

    authors: Kemali D

    更新日期:1989-01-01 00:00:00

  • Poor tolerability of a transdermal nicotine treatment in Parkinson's disease.

    abstract::Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200309000-00004

    authors: Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

    更新日期:2003-09-01 00:00:00

  • Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient.

    abstract::We report on a schizophrenic patient whose tardive dystonia, delusions, and auditory hallucinations showed remarkable concurrent improvement after replacing haloperidol with risperidone. The present finding suggests that the 5-hydroxytryptamine-2 (5-HT2) antagonistic action of risperidone has brought about the improve...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Yoshida K,Higuchi H,Hishikawa Y

    更新日期:1998-01-01 00:00:00

  • Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders.

    abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200311000-00009

    authors: Matsuda M,Hosoda W,Sekijima Y,Hoshi K,Hashimoto T,Itoh S,Ikeda S

    更新日期:2003-11-01 00:00:00

  • Plasma-level response relationships with fluoxetine and zimelidine.

    abstract::The results of pharmacokinetic studies of two recent 5-HT uptake inhibitors, zimelidine and fluoxetine, have pointed to the inadequacy of open-dose rising studies for establishing the most appropriate dose of new antidepressants. High plasma concentrations of the active metabolites, norzimelidine and norfluoxetine, we...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199001001-00008

    authors: Montgomery SA,Baldwin D,Shah A,Green M,Fineberg N,Montgomery D

    更新日期:1990-01-01 00:00:00

  • A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.

    abstract::Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/WNF.0b013e3181c46f48

    authors: Quagliato EM,Carelli EF,Viana MA

    更新日期:2010-01-01 00:00:00

  • L-tyrosine pharmacotherapy of schizophrenia: preliminary data.

    abstract::The utility of L-tyrosine (10 g/day in four divided doses) as an adjuvant to molindone (150 mg/day) in the treatment of schizophrenia was investigated using a placebo-controlled, double-blind crossover design (3 weeks on L-tyrosine, 3 weeks on placebo). The objective of this inpatient study was to increase dopaminergi...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199402000-00006

    authors: Deutsch SI,Rosse RB,Schwartz BL,Banay-Schwartz M,McCarthy MF,Johri SK

    更新日期:1994-02-01 00:00:00

  • Clinical pharmacology and mechanism of action of zonisamide.

    abstract::Antiepileptic drugs (AEDs) suppress seizures by selectively modifying the excitability of neurons and blocking seizure firing with minimal disturbance of nonepileptic activity. All AEDs have been shown to work by at least one of 3 main mechanisms of action: through modulation of voltage-gated ion channels, enhancement...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/wnf.0b013e3180413d7d

    authors: Biton V

    更新日期:2007-07-01 00:00:00

  • Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

    abstract::The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318223421f

    authors: da Rocha FF,Correa H

    更新日期:2011-07-01 00:00:00

  • Hypothermia induced by atypical neuroleptics.

    abstract::Hypothermia is a potentially life-threatening emergency. This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone. After the pipamperone dose was largely reduced, no further hypothermic episodes occurred. Nine other ca...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schwaninger M,Weisbrod M,Schwab S,Schröder M,Hacke W

    更新日期:1998-11-01 00:00:00

  • Combined quinacrine and chlorpromazine therapy in fatal familial insomnia.

    abstract::Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.wnf.0000134853.36429.0e

    authors: Benito-León J

    更新日期:2004-07-01 00:00:00

  • Relief of intractable posthypoxic myoclonus after administration of agomelatine.

    abstract::Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182613e06

    authors: González de la Aleja J,Saiz-Díaz RA,De la Peña P

    更新日期:2012-09-01 00:00:00

  • The reversibility of "permanent" tardive dyskinesia.

    abstract::Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198406000-00006

    authors: Klawans HL,Tanner CM,Barr A

    更新日期:1984-01-01 00:00:00

  • Color vision in Parkinson's disease: missing influence of amantadine sulphate.

    abstract::In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199510000-00009

    authors: Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

    更新日期:1995-10-01 00:00:00

  • Levodopa efficacy and pathological basis of Parkinson syndrome.

    abstract::Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00007

    authors: Rajput AH,Rozdilsky B,Rajput A,Ang L

    更新日期:1990-12-01 00:00:00

  • Metabolic and hormonal effects of dexfenfluramine on stress situations.

    abstract::Chronic treatment of rats with dexfenfluramine decreased the concentrations of circulating corticosterone, fatty acid, glycerol, and triacylglycerol after feeding a test load of fructose. It also decreased the rise in adrenalin in the blood of rats that were anaesthetized with urethane. These effects of dexfenfluramin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Brindley DN

    更新日期:1988-01-01 00:00:00

  • Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis.

    abstract::To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199302000-00009

    authors: Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

    更新日期:1993-02-01 00:00:00

  • Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

    abstract:OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013e31827db49b

    authors: Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

    更新日期:2013-01-01 00:00:00

  • Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.

    abstract::Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targe...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/WNF.0000000000000227

    authors: Schuster NM,Rapoport AM

    更新日期:2017-07-01 00:00:00

  • No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease.

    abstract::We studied the effect of chronic bromocriptine cotherapy on levodopa kinetics in seven patients with Parkinson's disease who were receiving levodopa therapy. Plasma levodopa concentrations were measured after a standard oral levodopa fasting dose over a 5-hour period, on two different sessions, without and with bromoc...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199212000-00008

    authors: Contin M,Riva R,Martinelli P,Albani F,Baruzzi A

    更新日期:1992-12-01 00:00:00

  • New treatment strategies for bacterial meningitis.

    abstract::Over the last several years, the therapeutic approach to bacterial meningitis has been changing. The neurological complications of bacterial meningitis result from an inflammatory process that is initiated by the lysis of bacteria in the subarachnoid space by antibiotics; to alter the pathophysiologic events initiated...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199310000-00001

    authors: Roos KL

    更新日期:1993-10-01 00:00:00

  • An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.

    abstract:BACKGROUND:BL-1020, a novel gamma aminobutyric acid (GABA) ester of perphenazine, is a new oral antipsychotic with a strong affinity for dopamine and serotonin receptors. Unlike first- and second-generation antipsychotics, it has agonist activity at GABA(A). OBJECTIVE:This is the first study to examine tolerability an...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/WNF.0b013e3181f8d501

    authors: Anand R,Geffen Y,Vasile D,Dan I

    更新日期:2010-11-01 00:00:00